Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma

14 Jul 2012

Abstract excerpt

IGF system contributes significantly to many human malignancies. Targeting IGF-I receptor (IGF-IR) has been reported to be active against several tumors, but particular efficacy was observed only against a minority of Ewing's sarcoma patients. Identification of mechanisms of acquired resistance to anti-IGF-IR agents is mandatory to individualize their use in clinics and optimize cure costs. In this study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Cytokine Signaling Pathways and Interactions
Share to Growth Hormone and Insulin-like Growth Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22798295
DOI: 10.1210/me.2012-1142

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's SarcomaPMID 22798295Read ↗

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 InhibitorsSemantic proximity Read ↗

Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma ModelSemantic proximity Read ↗

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapySemantic proximity Read ↗

Drugging IGF-1R in cancer: New insights and emerging opportunitiesSemantic proximity Read ↗

Insulin Receptor Isoforms and Insulin Growth Factor-like Receptors: Implications in Cell Signaling, Carcinogenesis, and ChemoresistanceSemantic proximity Read ↗

Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial LiteratureSemantic proximity Read ↗

Function of insulin‑like growth factor 1 receptor in cancer resistance to chemotherapy (Review)Semantic proximity Read ↗

The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable PerspectivesSemantic proximity Read ↗

Targeted Therapy of Ewing's SarcomaSemantic proximity Read ↗

A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAsSemantic proximity Read ↗

Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis.Semantic proximity Read ↗

Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of IGF1RSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.